Microarray market was valued at $5.8 billion in 2024 and is estimated to grow at a CAGR of 8.7% from 2025 to 2035. The increasing focus on personalized medicine owing to the rising prevalence of customized treatments based on individual genetic profiles is expected to drive market growth during the forecast period. The developments in personalized medicine facilitate the identification of disease-specific biomarkers, allowing for tailored treatment strategies. For instance, in March 2024, Nucleus Genomics launched a DNA analysis product that brings the benefits of personalized medicine to everyone. The customers earlier already had done genetic testing with older testing companies can upload their DNA data onto Nucleus. After uploading the data on the Nucleus platform, the customers can get greater insights into their genetic risk for diseases like type 2 diabetes, breast cancer, and many more. Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI. Additionally, the company further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI. The company has also been awarded CLIA certification and CAP accreditation for its WGS informatics laboratory in North Carolina. This ensures customer whole-genome sequencing results are highest and clinical-grade quality.
Browse the full report description of “Microarray Market Size, Share & Trends Analysis by Type (DNA Microarrays, Protein Microarray, Peptide Microarray, Tissue Microarray, and Others), By Application (Diagnosis & Prognosis, Pharmacogenomics & Theragnostic, Drug Discovery, and Others), Forecast Period (2025-2035)” at https://www.omrglobal.com/industry-reports/microarray-market
The key players in the microarray market are Agilent Technologies, Inc., Abcam Plc, Illumina, Inc., SCHOTT AG, and Thermo Fisher Scientific, Inc. among others among others. Such companies are at the forefront of innovation, continuously enhancing microarray fabrication techniques and exploring new applications across genomics, diagnostics, and drug discovery. For instance, in September 2023, Merck expanded mRNA capabilities and became the first to offer CTDMO (contract testing, development, and manufacturing organization). The company offers fully integrated services for every stage of mRNA development, manufacturing, and commercialization.
Market Coverage
• The market number available for – 2024-2035
• Base year- 2024
• Forecast period- 2025-2035
• Segment Covered-
o By Type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape - Agilent Technologies, Inc., Abcam Plc, Illumina, Inc., SCHOTT AG, and Thermo Fisher Scientific, Inc. among others
Key questions addressed by the report.
Global Microarray Market Report Segment
By Type
By Application
Global Microarray Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/microarray-market